The FDA granted fast track designation to urcosimod to treat neuropathic corneal pain, according to a press release from Okyo Pharma. Urcosimod, formerly called OK-101, is a “lipid conjugated chemerin ...

According to the latest study from BCC Research, the "Global Fluorescence Microscopy Market" is expected to grow from $968.5 ...

What if there were a fabric that, like Superman, could take a bullet and self-heal? Such a super-dynamic, action-powered ...

Urcosimod is a lipid conjugated ChemR23 chemerin peptide agonist that is designed to reduce inflammation and pain in the eye.

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod ...

"Life Sciences Drive Fluorescence Microscopy Market Growth Amid Rising Disease Prevalence and Technological Advances" BOSTON, April 30, 2025 /PRNewswire/ -- According to the latest study ...

This pilot study provides essential insights into how AI can augment traditional clinical workflows in diabetes management by ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP”) patients was initiated in October 2024 and designed as a ...

Scientists successfully 3D printed plant-based calamari rings using mung bean protein and microalgae, creating a seafood ...

Real-time CMXRF measurements track transition metal deposition in NMC lithium-ion batteries, crucial for improving ...

MIT's CircTrek enables real-time monitoring of circulating blood cells, providing critical data for timely medical interventions and improved patient care.